Data published in the International Journal of Nanobiotechnology
– New preclinical data (published in a peer-reviewed journal) from a model of anti-PD-1 resistant lung cancer shows that adding NBTXR3 to a combination of radiotherapy, anti-PD-1 and anti-CTLA-4 produced significant antitumor effects against primary and secondary tumors, improved mouse survival rate from 0% to 50%, and induced long-term antitumor memory.
– The data suggest that the potential immune system priming effect of NBTXR3 may go beyond anti-PD-1 and merits further investigation in preclinical and clinical settings.
Paris, France ; Cambridge, MA (USA); January 26, 2022 – NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”) is a French biotechnology company in late-stage clinical development, pioneering physics-based approaches to expand treatment options for cancer patients , announces today the publication, in the International Journal of Nanobiotechnology, of new preclinical data of the radioenhancer NBTXR3 in immunotherapy. NBTXR3 is a potential treatment for all solid tumors, alone or in combination with different anti-cancer agents.